Skip to main content

2020

Press release

Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with RUCONEST®

Pharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the extension of the indication for RUCONEST® received on 26 March 2020.

Read more

Filter

Cookies: This website uses cookies Check the cookies page for more information Accept Decline